Breadcrumb

null Melissa-Rosina Pasqua, MD, PhD

Junior Scientist, RI-MUHC, Glen site

Metabolic Disorders and Complications Program

Centre for Translational Biology

Assistant Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Endocrinology and Metabolism, MUHC

 

Keywords

type 1 diabetes • adjunctive therapy • diabetes technology • GLP1 agonists

Research Focus

My research focusses on using adjunctive therapy and diabetes technology to address gaps in type 1 diabetes care. I have published various studies involving the use of SGLT2 inhibitors and GLP-1 agonists to improve outcomes using automated insulin delivery in adults with type 1 diabetes. The gaps I am currently looking to address are glycemic control, metabolic syndrome/ obesity/ body composition, T1D screening, ketosis, hypoglycemia, and pathways to islet transplantation. My research methods include clinical trials, retrospective chart review, and qualitative analyses.

Selected Publications

Click on Pubmed to see my current publications list

  • Melissa-Rosina Pasqua, Joelle Doumat, Michael Tsoukas, Ahmad Haidar. Semaglutide use with automated insulin delivery in adults with type 1 diabetes: qualitative analyses and patient[1]reported outcomes from a randomized controlled trial. In-press the Canadian Journal of Diabetes, 2025. doi: https://doi.org/10.1016/j.jcjd.2025.10.175.

  • Melissa-Rosina Pasqua, Michael Tsoukas, Ahmad Haidar. Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: a post-hoc analysis of a double-blinded, randomized, crossover trial. Accepted by Diabetes, Obesity & Metabolism. DOI: 10.1111/dom.70213.

  • Kudva YC, ... Pasqua MR, ... Beck RW; 2IQP Study Group. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. N Engl J Med. 2025;392(18):1801-1812. DOI: 10.1056/NEJMoa2415948.

  • Pasqua, MR., Tsoukas, M.A., Kobayati, A. et al. Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nat Med (2025), 31(4):1239-1245. DOI: 10.1038/s41591-024-03463-z.

  • M-R Pasqua, A. Jafar, A. Kobayati, M. A. Tsoukas, A. Haidar. Low-dose empagliflozin improves therapy: a randomized cross-over controlled trial. Diabetes Care, 2023; 46 (1):165-172. DOI: 10.2337/dc22-0490.